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Inflammatory and immune responses are generated locally by the selective invasion and accumulation of the
immune cells into the lesion site. The infiltration process of the immune cells into the tissue from the blood
through the vascular endothelial cells is closely regulated by a number of chemotactic factors and cell adhesion
molecules.
Fractalkine (FKN)/CX3CL1 is a membrane-bound chemokine possessing a chemokine/mucin hybrid structure and a
transmembrane domain and has a dual function as an adhesion molecule and a chemoattractant. FKN is mainly
expressed on activated endothelial cells, activated fibroblasts, and osteoblasts. Its receptor, CX3CR1, is expressed on
cytotoxic effector lymphocytes, monocytes/macrophages, and osteoclasts. To date, a lot of key functional aspects of
the FKN-CX3CR1 axis has been identified: (1) the rapid capture and firm adhesion of immune cells to vascular
endothelial cells, (2) chemotaxis, (3) the enhancement of the transmigration to other chemokines, (4) the crawling
behavior of the monocytes that patrol on vascular endothelial cells, (5) the retention of monocytes as the accessory
cells of the inflamed endothelium to recruit inflammatory cells, and (6) the survival of the macrophage.
In this review, we will focus on the pathological role of FKN in rheumatoid arthritis (RA) and the physiological role
of FKN on osteoclast differentiation. Furthermore, we will discuss the therapeutic potential of anti-FKN mAb for RA
patients and its distinct mode of action from other cytokine inhibitors.
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Rheumatoid arthritis (RA) is a long-lasting auto-
immune disorder that primarily affects joints charac-
terized by synovial hyperplasia and bone erosion
associated with neovascularization, infiltration of pro-
inflammatory cells, and increased cytokine production.
Chemokines and their receptors control immune cell
trafficking and are crucial for the inflammatory
process. Fractalkine (FKN) is a unique membrane-
bound chemokine possessing multiple biological func-
tions. The FKN-CX3CR1 axis participates in the
patrol for tissue damages and the quick mobilization
and accumulation of immune cells to the sites of
danger. The FKN-CX3CR1 axis is also involved in the
pathogenesis in both bone-resorbing and inflammatory* Correspondence: t-imai@kan.eisai.co.jp
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(http://creativecommons.org/publicdomain/zediseases. Taken together, FKN-CX3CR1 is expected to
be a novel therapeutic target for RA by simultaneous
direct inhibition of inflammation and bone resorption.Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease characterized by the synovial hyperplasia, joint
destruction, and massive infiltration of lymphocytes
and macrophages into the synovium. Fibroblast-like
synoviocytes (FLSs) also play a major role in the
pathogenesis of RA by producing a variety of cyto-
kines, chemokines, and matrix-degrading enzymes
that mediate the interaction with neighboring inflam-
matory and endothelial cells. Chronic inflammatory
environments are responsible for the progressive in-
flammation in the joints and the destruction of the
articular cartilage and bone [1].rticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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that play an important role in the recruitment and activa-
tion of immune cells. They are subdivided into four sub-
families, C, CC, CXC, and CX3C chemokines, based on
the number and spacing of the amino-terminal, conserved
cysteine residues. The biological effects of chemokines are
mediated by their binding to the cognate receptors, seven-
transmembrane G protein-coupled receptors (GPCRs).
Over 50 chemokines and 19 receptors have been identi-
fied, for which complex ligand-receptor relationships are
revealed with high redundancy [2].
Chemokines are originally identified as potent attractants
for leukocytes such as neutrophils and monocytes and
therefore are generally considered as mediators of acute
inflammation (inflammatory chemokines). In addition, sev-
eral chemokines have been found to be constitutively
expressed in lymphoid and other tissues with individually
characteristic patterns. Lymphocytes also express chemo-
kine receptors with a cell-specific manner. Accumulating
evidence indicates that chemokines are important not only
in inflammation but also in the development, homeostasis,
and functions of the immune system that should be shaped
in a proper balance (immune or homeostatic chemokines).
In this review, we will discuss the roles of FKN, the
only member of the CX3C chemokine family, on inflam-
matory/immune diseases and its potential as a new
therapeutic target for RA.
Functions of the FKN-CX3CR1 axis
FKN is a membrane-bound chemokine possessing a
chemokine/mucin hybrid structure followed by a
transmembrane domain [3]. This interesting structure
allows FKN to work as an adhesion molecule in the
membrane-bound form or as a chemoattractant in the
soluble form shed by metalloproteases, a disintegrin
and metalloproteinase domain-containing protein
(ADAM) 10 or 17. Soluble FKN acts as a chemo-
attractant for monocytes, natural killer (NK) cells, and
T cells. The membrane-bound FKN on endothelial
cells mediates the rapid capture, integrin-independent
firm adhesion, and activation of circulating leukocytes
under flow by its direct binding to CX3CR1 [4, 5].
FKN is expressed on vascular endothelial cells and is
strongly enhanced by the stimulation with pro-
inflammatory cytokines, such as tumor necrosis factor-
α (TNF-α), interleukin-1 (IL-1), and interferon-γ (IFN-
γ). CX3CR1 is expressed on monocytes/macrophages
and perforin+/granzyme B+ cytotoxic lymphocytes in-
cluding NK cells and terminally differentiated cytotoxic
T cells [6]. Soluble FKN preferentially induced the mi-
gration of cytotoxic effector lymphocytes, and the
membrane-bound FKN promoted their subsequent mi-
gration to the secondary chemokines, such as the
macrophage inflammatory protein-1β/CCL4 or IL-8/CXCL8. Thus, FKN expressed on the inflamed endo-
thelium functions as a vascular regulator for cytotoxic
effector lymphocytes. Interestingly, it is revealed that a
subset of monocytes patrols healthy tissues through
long-range crawling on the resting endothelium by the
intravital imaging of blood monocytes [7]. This unique
behavior depends on the physical interaction-mediated
integrin LFA-1 and CX3CR1 and is required for rapid
accumulation of the monocytes to the site of danger to
initiate early immune response. Nr4a1-dependent
Ly6Clow CX3CR1high monocytes scan capillaries and
scavenge micrometric particles from their luminal side
in a steady state in the kidney cortex. Importantly, a
local TLR7-dependent danger signal increases the re-
tention time of Ly6Clow CX3CR1high monocytes on the
endothelium. These tethered monocytes are then acti-
vated and function as “accessory cells” of the endothe-
lium by orchestrating the focal necrosis of endothelial
cells by recruiting neutrophils and the in situ phagocyt-
osis of cellular debris by monocytes [8]. The FKN-
CX3CR1 axis also has been reported to increase the
survival of microglia and smooth muscle cells by Akt
activation in a PI3K-dependent manner [9]. Lionakis
et al. demonstrated that CX3CR1 promotes resident
macrophage survival by inhibiting caspase-dependent
apoptosis in the kidney in a mouse model of systemic
candidiasis [10].
These results indicate that the FKN-CX3CR1 axis partici-
pates in the patrol for tissue damages in normal conditions
and the quick mobilization and accumulation of effector
cells to the sites of danger (Fig. 1).
Role of the FKN-CX3CR1 axis in the pathogenesis
of RA
FKN is expressed on fibroblast-like synoviocyte (FLS) cells
and endothelial cells in the RA synovium and contributes
to the accumulation of T cells and macrophages, which ex-
press CX3CR1. The interaction between FKN and CX3CR1
is involved in the adhesion of the inflammatory cells to
endothelial cells, their migration into the synovium, and
cytokine production [1]. Nanki et al. showed that the per-
ipheral blood CX3CR1-expressing CD4+ and CD8+ T cells
preferentially produce IFN-γ, TNF-α, granzyme A, and per-
forin and that these cells are increased in patients with RA
[11]. Furthermore, FKN expression is up-regulated in endo-
thelial cells and FLSs in the synovium of RA patients, but
not in the osteoarthritis synovium. Thus, the FKN/CX3CR1
axis is likely to play an important role in the preferential in-
filtration of Th1 and Tc1 cells into the RA synovium, which
contributes to the pathogenesis of RA.
Macrophages are the primary source of pro-
inflammatory cytokines. A high percentage of macrophages
within the rheumatoid synovium express the CX3CR1 re-
ceptor. Circulating CD16+ monocytes express higher levels
Fig. 1 Multiple functions of FKN. Many key functional aspects of the FKN-CX3CR1 axis have been identified: (1) the rapid capture and firm adhesion of
immune cells to vascular endothelial cells, (2) chemotaxis, (3) the enhancement of the transmigration to other chemokines, (4) the crawling behavior of
the monocytes that patrol on vascular endothelial cells, (5) the retention of monocytes as the accessory cells of the inflamed endothelium to recruit
inflammatory cells, and (6) the survival of the macrophage
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and healthy subjects. High levels of CX3CR1 expression are
also seen in CD16+ monocytes localized to the lining layer
in RA synovial tissue, and soluble FKN efficiently induced
the chemotaxis of these cell populations [12, 13]. Yano
et al. postulated that the recruitment of CD16+ monocytes
may be the result of the chemoattractant properties of
FKN. Soluble FKN also induces IL-1 and IL-6 secretion
from activated monocytes suggesting a crucial pro-
inflammatory effect of FKN on monocyte function [12].
FLSs, which are resident cells in the sublining region and
markedly expanded in the RA synovium, have been linked
with a number of deleterious effects in RA. FLSs produce
pro-inflammatory cytokines, exhibit a capacity for antigen
presentation, and induce T cell expansion [14]. FKN is also
expressed on cultured synovial fibroblasts and hyperplastic
synoviocytes in RA. The senescent CD4+CD28− T cells
that accumulate in the RA synovium aberrantly express
CX3CR1. FKN, which is induced on FLSs by stimulation
with pro-inflammatory cytokines, strongly induces the ad-
hesion of CD4+CD28−CX3CR1+ T cells, provides survival
signals and amplified proliferation, and stimulates the pro-
duction of pro-inflammatory cytokines as well as the expul-
sion of cytoplasmic granules [15]. Thus, membrane-bound
FKN may act as a co-stimulatory signal for CD4+CX3CR1
+ T cells in the RA synovium.
In the collagen-induced arthritis (CIA) model in mice,
the prophylactic treatment of anti-FKN monoclonal
antibody (mAb) significantly improves the clinical arth-
ritis score and reduces the infiltration of inflammatory
cells, and bone erosion in the synovium, suggesting that
anti-FKN mAb ameliorates arthritis by inhibiting the in-
filtration of inflammatory cells into the synovium [16].In addition, our recent studies have shown that the
therapeutic treatment of anti-FKN mAb also meliorates
arthritis symptoms and radiological score in the CIA
model (manuscript in preparation).
Role of the FKN-CX3CR1 axis in bone destruction
Osteoclast precursors selectively express CX3CR1,
whereas FKN is expressed on osteoblasts. FKN on the
osteoblasts is involved in the osteoblast-induced osteo-
clast differentiation [17]. Soluble FKN induces the mi-
gration of bone marrow cells containing osteoclast
precursors, whereas immobilized FKN mediates the firm
adhesion of osteoclast precursors. Furthermore, the
blockade of FKN efficiently inhibits osteoclast differenti-
ation from mouse bone marrow cells when co-cultured
with osteoblasts. Consistently, an in vivo experiment in
neonatal mice shows that anti-FKN mAb significantly
suppresses bone resorption by reducing the number of
bone-resorbing mature osteoclasts.
In the analysis of the femoral bone tissues of heterozy-
gous CX3CR1−EGFP knock-in mice, CX3CR1−EGFP+
cells are shown to differentiate into tartrate-resistant acid
phosphatase (TRAP)+ mature osteoclasts. CX3CR1−EGFP
+ but not CX3CR1−EGFP− cells sorted from bone marrow
cells efficiently differentiate into TRAP+ mature osteoclast-
like cells in vitro in the presence of RANKL, indicating that
CX3CR1+ cells in the bone marrow are osteoclast precur-
sors [18, 19].
The role of the FKN-CX3CR1 axis in osteoclast re-
cruitment and osteoclastogenesis is evaluated by an irra-
diated murine model. FKN is dramatically up-regulated
in the skeletal vascular endothelium after ionizing radi-
ation (IR). The induced FKN promotes the recruitment
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the bone remodeling surface in the irradiated bones and
enhances subsequent bone resorption. In vivo experi-
ments also show that the blockade of the FKN-CX3CR1
axis ameliorates osteoclastogenesis and prevented bone
loss after IR [20].
Collectively, FKN plays an important role in osteoclast re-
cruitment and differentiation, possibly through its dual
functions as a chemotactic factor and an adhesion molecule
for CX3CR1+ osteoclast precursors. The FKN-CX3CR1
axis may be a novel target for the therapeutic intervention
of bone-resorbing diseases such as RA and osteoporosis.
Development of the first humanized anti-FKN
mAb, KANAb001 (E6011)
KANAb001 (E6011) is the first humanized anti-FKN mAb,
generated by KAN Research Institute, Inc. Currently, phase
1/2 clinical studies of E6011 are ongoing in both RA andFig. 2 E6011 targets CX3CR1+ cells in the inflammatory sites in RA. The int
promotes the osteoclast differentiation. The macrophage may be recruited
the macrophage helps to activate the synovial sublining fibroblasts throug
expressed on the cytotoxic effector CD4+ T cell binds to FKN on the fibroblas
TNF-α up-regulates FKN production as a growth factor of synovial fibroblasts,
Taken together, the interaction of FLS with the macrophage and T cells throu
and joint destructionCrohn’s disease in Japan by Eisai Co., Ltd. Recently, we have
reported that E6011 is safe and well tolerated and has a
promising efficacy in active RA patients with MTX or TNF
inhibitor-inadequate response (MTX-IR or TNFi-IR) at the
American College of Rheumatology 2015. While further
clinical studies are required, the results obtained to date in-
dicate that a novel biological DMARD targeting the FKN-
CX3CR1 axis will be clinically beneficial for active RA
patients.
Most of current marketed mAbs inhibit specific cyto-
kines and cytokine receptors, and JAK inhibitors block
the effect of multiple cytokines by targeting cytokine
signaling. On the other hand, E6011 targets the cell
trafficking of immune cells, which produce multiple
pro-inflammatory cytokines in the local inflamed sites.
Previous studies have demonstrated that anti-FKN
mAb inhibit the migration of both CX3CR1+ macro-
phages producing pro-inflammatory cytokines (TNF-α,eraction of the osteoclast precursor with osteoblasts via FKN-CX3CR1
by FLS-induced chemokine production through FKN-CX3CR1. In turn,
h the production of inflammatory cytokines such as TNF-α. CX3CR1
t. And then, T cell-FLS communication activates the TNF-α production.
and TNF-α also induces the MMP3 expression, matrix metalloproteinase.
gh FKN-CX3CR1 may contribute to the enhancement of inflammation
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cells containing cytotoxic molecules (granzyme B and
perforin). These results indicate that anti-FKN mAb
has a potential to block the most upstream step of the
inflammation cascade in the local inflamed region. In
addition, anti-FKN mAb suppresses the bone resorp-
tion by inhibiting osteoclast differentiation. Taken to-
gether, E6011 is expected to have strong preventive
effects on joint destruction with a unique dual mode of
action based on the inhibition of the immune cell traf-
ficking and the direct suppression of osteoclastogenesis
in local environments (Fig. 2).
Conclusions
FKN is a unique chemokine possessing a dual function
as a chemoattractant and an adhesion molecule for
CX3CR1-expressing monocytes, cytotoxic effector lym-
phocytes, and osteoclast precursors. Increasing evidence
indicates that FKN is involved in the pathological roles
of inflammatory disease such as RA. Now, clinical trials
of E6011, the first humanized anti-FKN mAb, are on-
going in Japan. It is expected that E6011 will open up
the possibility of a new therapeutic strategy for the treat-
ment of RA with a novel mode of action distinct from
other cytokine/cytokine receptor inhibitors (infliximab,
tocilizumab, etc.) and modulator of T cell co-stimulation
(abatacept).
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